Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars

Bevacizumab And Trastuzumab Rivals Grow Ahead Of Adalimumab Launch

 
• By David Wallace
  
Two Billion Dollars $2bn Icon
For the second year running, Pfizer’s biosimilars sales exceeded $2bn • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products